These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 20406744)

  • 1. Trends in the application of dynamic allocation methods in multi-arm cancer clinical trials.
    Pond GR; Tang PA; Welch SA; Chen EX
    Clin Trials; 2010 Jun; 7(3):227-34. PubMed ID: 20406744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of industry sponsorship to published outcomes in gastrointestinal clinical research.
    Brown A; Kraft D; Schmitz SM; Sharpless V; Martin C; Shah R; Shaheen NJ
    Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1445-51. PubMed ID: 17101295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgeons: A Future Role in Clinical Trials?
    Rusch VW
    Oncologist; 1997; 2(3):V-VI. PubMed ID: 10388050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.
    Stone AM; Bushnell W; Denne J; Sargent DJ; Amit O; Chen C; Bailey-Iacona R; Helterbrand J; Williams G;
    Eur J Cancer; 2011 Aug; 47(12):1763-71. PubMed ID: 21435858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Participant expectancies in double-blind randomized placebo-controlled trials: potential limitations to trial validity.
    Colagiuri B
    Clin Trials; 2010 Jun; 7(3):246-55. PubMed ID: 20421243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between pharmaceutical involvement and outcomes in breast cancer clinical trials.
    Peppercorn J; Blood E; Winer E; Partridge A
    Cancer; 2007 Apr; 109(7):1239-46. PubMed ID: 17326054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II cancer clinical trials with a one-sample log-rank test and its corrections based on the Edgeworth expansion.
    Sun X; Peng P; Tu D
    Contemp Clin Trials; 2011 Jan; 32(1):108-13. PubMed ID: 20888929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statistical comparison of random allocation methods in cancer clinical trials.
    Hagino A; Hamada C; Yoshimura I; Ohashi Y; Sakamoto J; Nakazato H
    Control Clin Trials; 2004 Dec; 25(6):572-84. PubMed ID: 15588744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methodology standards associated with quality reporting in clinical studies in pediatric surgery journals.
    Thakur A; Wang EC; Chiu TT; Chen W; Ko CY; Chang JT; Atkinson JB; Fonkalsrud EW; Grosfeld JL
    J Pediatr Surg; 2001 Aug; 36(8):1160-4. PubMed ID: 11479847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control of selection bias in parallel-group controlled clinical trials in dogs and cats: 97 trials (2000-2005).
    Brown DC
    J Am Vet Med Assoc; 2006 Sep; 229(6):990-3. PubMed ID: 16978121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statistical considerations for the design and analysis of Phase III clinical trials in prostate cancer.
    Halabi S
    Urol Oncol; 2008; 26(3):300-7. PubMed ID: 18452825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-arm clinical trials of new agents: some design considerations.
    Freidlin B; Korn EL; Gray R; Martin A
    Clin Cancer Res; 2008 Jul; 14(14):4368-71. PubMed ID: 18628449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reporting on methods in clinical trials.
    DerSimonian R; Charette LJ; McPeek B; Mosteller F
    N Engl J Med; 1982 Jun; 306(22):1332-7. PubMed ID: 7070458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase II designs in cancer clinical trials: current status and future directions.
    Lee JJ; Feng L
    J Clin Oncol; 2005 Jul; 23(19):4450-7. PubMed ID: 15994154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allocation of patients to conditions in headache clinical trials: randomization, stratification, and treatment matching.
    Lipchik GL; Nicholson RA; Penzien DB
    Headache; 2005 May; 45(5):419-28. PubMed ID: 15953258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five-year change in statistical designs of phase II trials published in leading cancer journals.
    Thezenas S; Duffour J; Culine S; Kramar A
    Eur J Cancer; 2004 May; 40(8):1244-9. PubMed ID: 15110889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sample size calculation in survival trials accounting for time-varying relationship between noncompliance and risk of outcome event.
    Li B; Grambsch P
    Clin Trials; 2006; 3(4):349-59. PubMed ID: 17060209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Designing for cancer clinical trials: selection of prognostic factors.
    Brown BW
    Cancer Treat Rep; 1980; 64(2-3):499-502. PubMed ID: 7407790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency, nature, effects, and correlates of conflicts of interest in published clinical cancer research.
    Jagsi R; Sheets N; Jankovic A; Motomura AR; Amarnath S; Ubel PA
    Cancer; 2009 Jun; 115(12):2783-91. PubMed ID: 19434666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.